Search research articles
Contact Us
Filters
Showing results (151-160 of 227) with videos related to
Page
of 23
Sort By:
Cancer
|
April 30, 2009
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference
Michael B Atkins, Ronald M Bukowski, Bernard J Escudier, et al.
European Urology
|
March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Bernard Escudier, Padmanee Sharma, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2024
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Brian I Rini, Dena Battle, Robert A Figlin, et al.
BJU International
|
April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
Sumanta K Pal, David F McDermott, Michael B Atkins, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2020
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
Michael B Atkins, Brian I Rini, Robert J Motzer, et al.
Page
of 23
Search research articles
Search
Showing results (151-160 of 227) with videos related to
Sort By:
Page
of 23
Cancer
|
April 30, 2009
Innovations and challenges in renal cancer: summary statement from the Third Cambridge Conference
Michael B Atkins, Ronald M Bukowski, Bernard J Escudier, et al.
European Urology
|
March 7, 2017
CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma
Bernard Escudier, Padmanee Sharma, David F McDermott, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 2, 2021
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma
David F McDermott, Jae-Lyun Lee, Marek Ziobro, et al.
Journal for Immunotherapy of Cancer
|
July 26, 2024
Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of CheckMate 214
Charlene M Mantia, Opeyemi A Jegede, Elizabeth R Plimack, et al.
Journal for Immunotherapy of Cancer
|
November 20, 2024
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Ulka N Vaishampayan, Jameel Muzaffar, Ira Winer, et al.
Journal for Immunotherapy of Cancer
|
December 21, 2019
The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)
Brian I Rini, Dena Battle, Robert A Figlin, et al.
BJU International
|
April 2, 2020
Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma
Sumanta K Pal, David F McDermott, Michael B Atkins, et al.
Journal for Immunotherapy of Cancer
|
March 22, 2023
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 20, 2022
Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A)
Michael B Atkins, Opeyemi A Jegede, Naomi B Haas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2020
Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab <b>+</b> Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma
Michael B Atkins, Brian I Rini, Robert J Motzer, et al.
Page
of 23